Back in 2009, Johnson and Johnson bought Cougar Biotech here in Los Angeles, who has not yet brought a product to market, but it appears from the results with 
the latest reports on their prostate cancer drug, it might soon be in the works for submission to the FDA.
Johnson and Johnson Acquiring Cougar Biotechnology – Cancer Biotech Company Los Angeles
Below from the Cougar website you can see the progress with abiraterone in the pipeline. This study was conducted in Europe. The drug works by keep the production of testosterone at a minimal level to keep tumors from growing. Right now there’s no word on what the cost would be and I would assume that type of information will flow later. BD
NEW BRUNSWICK, N.J. (TheStreet) -- Advanced prostate cancer patients that no longer respond to chemotherapy survived about four months longer after treatment with Johnson & Johnson's(JNJ_) experimental drug abiraterone compared to similar patients treated with a placebo, according to data from a phase III study presented Monday.
Johnson & Johnson announced top-line results from the positive study of abiraterone last month and said it was evaluating plans to seek the drug's approval. Detailed data, including the extent of abiraterone's survival benefit, were presented for the first time today at the European Society of Medical Oncology (ESMO) annual meeting.
J&J Prostate Cancer Drug Prolongs Survival - TheStreet
0 comments :
Post a Comment